Oncology

Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!

October 6, 2009
Cornelis van de Velde

Cornelis van de Velde

Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer–analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.

Download this interview

Add podcast to iTunes

Similar Interviews

  • ASCO Audio Journal of Oncology in Advance – February 15th, 2007 – reporting from San Antonio Breast Cancer Symposium, December 13-17, 2007

    • Rachel Johnson

  • For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival

    • [caption id="attachment_984" align="alignnone" width="120" caption="Charles Coombes"][/caption]Charles Coombes at ECCO15-ESMO34 on the Intergroup Exemestane Study showing a big increase in survival

  • Audio Journal of Oncology Breast Cancer Special 2005

    • Reporting from: - San Antonio Breast Cancer Symposium, December 8-11, 2004 - European Society for Medical Oncology Congress, October 29-November 10,

    1. Honestly, your website is very good for a foreign medical student to learn the pertaining knowledge. However, I want to know, is there any text summary for the recording?

      Posted by monyaren | January 23, 2010, 8:28 am

    Post a comment